Survival and risk of AML evolution according to the main clinical and hematologic characteristics at diagnosis in the training cohort
| Characteristic . | OS . | AML evolution . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of patients (%) . | Median (mo) . | Proportion alive at 5 y (%) . | Log-rank (P value) . | Time to 25% probability (mo) . | Cumulative probability of AML evolution (%) . | Log-rank (P value) . | ||
| 2 y . | 5 y . | |||||||
| Overall | 558 (100) | 31 | 31 | 38 | 17 | 29 | ||
| Age, y | .008 | .071 | ||||||
| <70 | 190 (34) | 37 | 37 | 28 | 22 | 34 | ||
| ≥70 | 207 (66) | 28 | 27 | 39 | 15 | 25 | ||
| Gender | .021 | .074 | ||||||
| Male | 377 (68) | 29 | 28 | 30 | 17 | 34 | ||
| Female | 181 (32) | 42 | 36 | 66 | 17 | 22 | ||
| WHO subtype | <.001 | <.001 | ||||||
| CMML-1 | 478 (86) | 37 | 34 | 59 | 13 | 25 | ||
| CMML-2 | 80 (14) | 12 | 12 | 10 | 47 | 54 | ||
| Hemoglobin level, g/dL | <.001 | <.001 | ||||||
| <10 | 190 (34) | 18 | 16 | 19 | 29 | 40 | ||
| ≥10 | 368 (66) | 43 | 38 | 60 | 13 | 25 | ||
| Hemoglobin level, g/dL | <.001 | .015 | ||||||
| <8 in females and <9 in males | 91 (16) | 13 | 12 | 20 | 30 | 40 | ||
| ≥8 in females and ≥9 in males | 467 (84) | 38 | 35 | 40 | 16 | 28 | ||
| Leukocyte count, × 109/L | <.001 | <.001 | ||||||
| <13 (CMML-MD FAB subtype) | 338 (61) | 44 | 42 | 73 | 14 | 20 | ||
| ≥13 (CMML-MP FAB subtype) | 220 (39) | 21 | 16 | 25 | 23 | 49 | ||
| Platelet count, × 109/L | .054 | .850 | ||||||
| <100 | 221 (40) | 30 | 29 | 35 | 21 | 30 | ||
| ≥100 | 337 (60) | 36 | 32 | 57 | 15 | 28 | ||
| Neutrophil count, × 109/L | .021 | .470 | ||||||
| <1.8 | 101 (18) | 53 | 42 | 60 | 20 | 24 | ||
| ≥1.8 | 457 (82) | 29 | 29 | 38 | 17 | 31 | ||
| Monocyte count, × 109/L | .001 | .068 | ||||||
| <3 | 234 (57) | 42 | 40 | 83 | 14 | 20 | ||
| ≥3 | 182 (43) | 26 | 21 | 35 | 17 | 34 | ||
| Blasts in PB | <.001 | <.001 | ||||||
| Absent | 367 (77) | 39 | 34 | 60 | 12 | 25 | ||
| Present | 100 (21) | 15 | 11 | 12 | 39 | 48 | ||
| Blasts in BM, % | <.001 | <.001 | ||||||
| <5 | 347 (62) | 36 | 34 | 59 | 12 | 26 | ||
| 5-9 | 138 (25) | 43 | 35 | 60 | 16 | 24 | ||
| 10-19 | 73 (13) | 11 | 10 | 9 | 49 | 58 | ||
| LDH level, U/L | <.001 | .456 | ||||||
| ≤480 | 242 (68) | 43 | 43 | 65 | 14 | 25 | ||
| >480 | 115 (32) | 20 | 11 | 26 | 14 | 25 | ||
| Ferritin level, mg/dL | <.001 | <.001 | ||||||
| ≤500 | 173 (80) | 42 | 35 | 83 | 10 | 15 | ||
| >500 | 43 (20) | 20 | 16 | 13 | 30 | 48 | ||
| RBC transfusion dependency* | <.001 | <.001 | ||||||
| No | 441 (79) | 40 | 38 | 59 | 14 | 25 | ||
| Yes | 116 (21) | 14 | 9 | 14 | 32 | 47 | ||
| CMML-specific cytogenetic risk classification† | <.001 | <.001 | ||||||
| Low | 429 (81) | 39 | 36 | 60 | 12 | 24 | ||
| Intermediate | 47 (9) | 18 | 20 | 12 | 31 | 45 | ||
| High | 56 (10) | 12 | 7 | 11 | 56 | 67 | ||
| Characteristic . | OS . | AML evolution . | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of patients (%) . | Median (mo) . | Proportion alive at 5 y (%) . | Log-rank (P value) . | Time to 25% probability (mo) . | Cumulative probability of AML evolution (%) . | Log-rank (P value) . | ||
| 2 y . | 5 y . | |||||||
| Overall | 558 (100) | 31 | 31 | 38 | 17 | 29 | ||
| Age, y | .008 | .071 | ||||||
| <70 | 190 (34) | 37 | 37 | 28 | 22 | 34 | ||
| ≥70 | 207 (66) | 28 | 27 | 39 | 15 | 25 | ||
| Gender | .021 | .074 | ||||||
| Male | 377 (68) | 29 | 28 | 30 | 17 | 34 | ||
| Female | 181 (32) | 42 | 36 | 66 | 17 | 22 | ||
| WHO subtype | <.001 | <.001 | ||||||
| CMML-1 | 478 (86) | 37 | 34 | 59 | 13 | 25 | ||
| CMML-2 | 80 (14) | 12 | 12 | 10 | 47 | 54 | ||
| Hemoglobin level, g/dL | <.001 | <.001 | ||||||
| <10 | 190 (34) | 18 | 16 | 19 | 29 | 40 | ||
| ≥10 | 368 (66) | 43 | 38 | 60 | 13 | 25 | ||
| Hemoglobin level, g/dL | <.001 | .015 | ||||||
| <8 in females and <9 in males | 91 (16) | 13 | 12 | 20 | 30 | 40 | ||
| ≥8 in females and ≥9 in males | 467 (84) | 38 | 35 | 40 | 16 | 28 | ||
| Leukocyte count, × 109/L | <.001 | <.001 | ||||||
| <13 (CMML-MD FAB subtype) | 338 (61) | 44 | 42 | 73 | 14 | 20 | ||
| ≥13 (CMML-MP FAB subtype) | 220 (39) | 21 | 16 | 25 | 23 | 49 | ||
| Platelet count, × 109/L | .054 | .850 | ||||||
| <100 | 221 (40) | 30 | 29 | 35 | 21 | 30 | ||
| ≥100 | 337 (60) | 36 | 32 | 57 | 15 | 28 | ||
| Neutrophil count, × 109/L | .021 | .470 | ||||||
| <1.8 | 101 (18) | 53 | 42 | 60 | 20 | 24 | ||
| ≥1.8 | 457 (82) | 29 | 29 | 38 | 17 | 31 | ||
| Monocyte count, × 109/L | .001 | .068 | ||||||
| <3 | 234 (57) | 42 | 40 | 83 | 14 | 20 | ||
| ≥3 | 182 (43) | 26 | 21 | 35 | 17 | 34 | ||
| Blasts in PB | <.001 | <.001 | ||||||
| Absent | 367 (77) | 39 | 34 | 60 | 12 | 25 | ||
| Present | 100 (21) | 15 | 11 | 12 | 39 | 48 | ||
| Blasts in BM, % | <.001 | <.001 | ||||||
| <5 | 347 (62) | 36 | 34 | 59 | 12 | 26 | ||
| 5-9 | 138 (25) | 43 | 35 | 60 | 16 | 24 | ||
| 10-19 | 73 (13) | 11 | 10 | 9 | 49 | 58 | ||
| LDH level, U/L | <.001 | .456 | ||||||
| ≤480 | 242 (68) | 43 | 43 | 65 | 14 | 25 | ||
| >480 | 115 (32) | 20 | 11 | 26 | 14 | 25 | ||
| Ferritin level, mg/dL | <.001 | <.001 | ||||||
| ≤500 | 173 (80) | 42 | 35 | 83 | 10 | 15 | ||
| >500 | 43 (20) | 20 | 16 | 13 | 30 | 48 | ||
| RBC transfusion dependency* | <.001 | <.001 | ||||||
| No | 441 (79) | 40 | 38 | 59 | 14 | 25 | ||
| Yes | 116 (21) | 14 | 9 | 14 | 32 | 47 | ||
| CMML-specific cytogenetic risk classification† | <.001 | <.001 | ||||||
| Low | 429 (81) | 39 | 36 | 60 | 12 | 24 | ||
| Intermediate | 47 (9) | 18 | 20 | 12 | 31 | 45 | ||
| High | 56 (10) | 12 | 7 | 11 | 56 | 67 | ||
RBC transfusion dependency was defined as having at least 1 RBC transfusion every 8 weeks over a period of 4 months.
CMML-specific cytogenetic risk classification: low, normal and isolated –Y; intermediate, other abnormalities; and high, trisomy 8, complex karyotype (≥3 abnormalities), and abnormalities of chromosome 7.